AMENDMENT UNDER 37 C.F.R. § 1.116 Attorney Docket No.: Q97193

Application No.: 10/599,290

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

**LISTING OF CLAIMS:** 

1. (currently amended): A skin-care composition containing 20-O-β-D-

glucopyranosyl-20(S)- protopanaxatriol (ginsenoside F1) and (-)epigallocatechin-3-

gallate (EGCG) as active ingredients, wherein the weight ratio of ginsenoside F1: EGCG

is in the range of 1:01-1:10; and wherein said ginsenoside F1 and EGCG are incorporated

in a combined amount of 0.0001% to 10% by weight based on the total weight of the

composition.

2. (original): The composition according to Claim 1, wherein said skin-care

is obtained by the apoptosis-inhibitory effect of said active ingredients.

3. (canceled). The composition according to Claim 2, wherein said

apoptosis is apoptotic cell death induced by low dose of UV irradiation

4. (currently amended): The composition according to Claims 2 or 3 claim

2, wherein said apoptosis-inhibitory effect is obtained by regulating the expression of

Bcl-2.

2

AMENDMENT UNDER 37 C.F.R. § 1.116 Attorney Docket No.: Q97193

Application No.: 10/599,290

5. (original): The composition according to Claim 4, wherein said regulation

of Bcl-2 expression is obtained by regulating the expression of Brn-3a.

6-7. (canceled).

8. (currently amended): An inhibitor of Rb protein dephosphorylation

containing ginsenoside F1 and EGCG as active ingredients, wherein the weight ratio of

ginsenoside F1 : EGCG is in the range of 1:0.1-1:10 and wherein said ginsenoside F1

and EGCG are incorporated in a combined amount of 0.0001% to 10% by weight based

on the total weight of the composition.

9. (currently amended): An inhibitor of skin damage for preventing cellular

damage caused by exposure to ultraviolet rays, containing a combination of low

concentrations of ginsenoside F1 and EGCG as an active ingredient, wherein the weight

ratio of ginsenoside F1: EGCG is in the range of 1:0.1-1:10 and wherein said

ginsenoside F1 and EGCG are incorporated in a combined amount of 0.0001% to 10% by

weight based on the total weight of the composition.

10. (currently amended): An external composition for skin care containing a

combination of ginsenoside F1 and EGCG as an active ingredient, wherein the weight

ratio of ginsenoside F1: EGCG is in the range of 1:0.1 – 1: 10 and wherein said

3

AMENDMENT UNDER 37 C.F.R. § 1.116 Attorney Docket No.: Q97193

Application No.: 10/599,290

ginsenoside F1 and EGCG are incorporated in a combined amount of 0.0001% to 10% by weight based on the total weight of the composition.

11. (new): The composition according to claim 1, wherein the weight ratio of

ginsenoside F1: EGCG is 1:5.